Phio Pharmaceuticals Corp. Announces Executive and Director Changes

Ticker: PHIO · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1533040

Phio Pharmaceuticals Corp. 8-K Filing Summary
FieldDetail
CompanyPhio Pharmaceuticals Corp. (PHIO)
Form Type8-K
Filed DateJun 12, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, filing, corporate-governance

TL;DR

Phio Pharma shakes up leadership and exec pay, files financials.

AI Summary

Phio Pharmaceuticals Corp. announced on June 6, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers. This filing also includes financial statements and exhibits.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in executive and director roles can indicate internal restructuring or strategic shifts that may carry inherent risks.

Key Players & Entities

  • Phio Pharmaceuticals Corp. (company) — Registrant
  • June 6, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Marlborough, Massachusetts (location) — Principal executive offices

FAQ

What specific roles have seen departures or appointments?

The filing indicates the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for certain officers, though specific names and roles are not detailed in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 6, 2025.

What is the state of incorporation for Phio Pharmaceuticals Corp.?

Phio Pharmaceuticals Corp. is incorporated in Delaware.

Where are Phio Pharmaceuticals Corp.'s principal executive offices located?

The principal executive offices are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.

What other items are included in this 8-K filing besides executive and director changes?

The filing also includes financial statements and exhibits.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Phio Pharmaceuticals Corp. (PHIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.